SCHEMBL3470797

SCHEMBL3470797

FC(F)(F)c1cc(-c2cccs2)n(-c2ccccc2Cl)n1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.56
NR1H2 P55055 5/20 0.56
NR1H3 Q13133 5/20 0.56
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NR3C2 P08235 1/20 0.47
HTT P42858 3/20 0.45
HPGD P15428 2/20 0.45
LMNA P02545 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CNR1 P21554 1/20 0.43
TP53 P04637 1/20 0.42
PTGS1 P23219 4/20 0.42
PTGS2 P35354 3/20 0.42
TNFSF11 O14788 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3477572 0.82 RXRA (0.54) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL8638930 0.80 PTGS2 (0.46) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL3474105 0.78 RXRA (0.64) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL3474650 0.76 RXRA (0.67) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3472539 0.76 RXRA (0.56) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3472018 0.76 RXRA (0.66) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL7316037 0.75 KDM4E (0.56) KDM4EALDH1A1L3MBTL1HTTHPGD
SCHEMBL6373168 0.75 RXRA (0.67) RXRANR1H2NR1H3NR3C2LMNA
SCHEMBL15641689 0.75 RXRA (0.60) RXRANR1H2NR1H3NR3C2NPSR1
SCHEMBL3470766 0.75 RXRA (0.64) RXRANR1H2NR1H3NR3C2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.